Enlivex (ENLV) has released an update.
Enlivex Therapeutics Ltd. has gained Israeli Ministry of Health approval to begin a Phase I clinical trial for Allocetra™, targeting treatment of psoriatic arthritis, a condition affecting up to 30% of psoriasis patients. The trial will focus on the safety and efficacy of Allocetra™ for those who haven’t responded to existing therapies. This development could potentially offer a new treatment option for patients coping with the chronic and often debilitating joint condition.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
